Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection : a Review
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: The aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections.
RECENT FINDINGS: Individuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic agents, and studies suggest that they are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications with a patient-centric approach are the most recognized methods for preventing critical long-term complications including genitourinary manifestations of diabetes. The available data regarding the association of SGLT-2 inhibitors with genitourinary infections is more comprehensive compared to that with UTIs. Further research is needed to better understand the mechanisms underlining the association between SGLT-2 inhibitors and genital infections and UTIs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current diabetes reports - 24(2024), 5 vom: 07. Mai, Seite 108-117 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pishdad, Reza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asymptomatic bacteriuria |
|---|
| Anmerkungen: |
Date Completed 24.04.2024 Date Revised 09.05.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11892-024-01537-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369172094 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369172094 | ||
| 003 | DE-627 | ||
| 005 | 20240509232445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11892-024-01537-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1402.xml |
| 035 | |a (DE-627)NLM369172094 | ||
| 035 | |a (NLM)38427314 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pishdad, Reza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection |b a Review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2024 | ||
| 500 | |a Date Revised 09.05.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: The aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections | ||
| 520 | |a RECENT FINDINGS: Individuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic agents, and studies suggest that they are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications with a patient-centric approach are the most recognized methods for preventing critical long-term complications including genitourinary manifestations of diabetes. The available data regarding the association of SGLT-2 inhibitors with genitourinary infections is more comprehensive compared to that with UTIs. Further research is needed to better understand the mechanisms underlining the association between SGLT-2 inhibitors and genital infections and UTIs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Asymptomatic bacteriuria | |
| 650 | 4 | |a Candida vulvovaginal infection | |
| 650 | 4 | |a Genitourinary infection | |
| 650 | 4 | |a SGLT-2 inhibitors | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 4 | |a UTI | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Auwaerter, Paul G |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyani, Rita R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current diabetes reports |d 2001 |g 24(2024), 5 vom: 07. Mai, Seite 108-117 |w (DE-627)NLM12416935X |x 1539-0829 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:5 |g day:07 |g month:05 |g pages:108-117 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11892-024-01537-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 5 |b 07 |c 05 |h 108-117 | ||